Marché mondial de la glomérulosclérose segmentaire focale – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse du marché et de la taille de la glomérulosclérose segmentaire focale

Le marché de la glomérulosclérose segmentaire focale devrait connaître une croissance significative au cours de la période de prévision. L'incidence de la glomérulosclérose segmentaire focale est relativement élevée par rapport à d'autres maladies glomérulaires. Actuellement, il n'existe aucune thérapie approuvée par la FDA pour la glomérulosclérose segmentaire focale. La taille du marché thérapeutique de la glomérulosclérose segmentaire focale aux États-Unis représente principalement les options de traitement hors AMM, telles que la thérapie non immunitaire en association avec l'immunothérapie.

Data Bridge Market Research analyse que le marché mondial de la glomérulosclérose segmentaire focale, qui était de 24,01 milliards USD en 2023, devrait grimper en flèche pour atteindre 47,50 milliards USD d'ici 2031 et devrait connaître un TCAC de 8,9 % au cours de la période de prévision. Les « hôpitaux » dominent le segment des utilisateurs finaux du marché en raison d'une sensibilisation croissante au traitement approprié. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également des analyses approfondies d'experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché de la glomérulosclérose segmentaire focale

Market Definition

Focal segmental glomerulosclerosis is a type of renal disorder affecting the small filtering unit of kidneys called glomeruli which involves scarring of kidney. It is caused by numerous factors such as autoimmune disorders, genetic factors, and infection in other parts of the body and sclerotic diseases. It is one of the rare diseases that affects kidney function by damaging and attacking the glomeruli. Kidney defects typically characterize this disease by obesity, sickle cell anemia, obstructive sleep apnea, birth, and viruses such as HIV.

Global Focal Segmental Glomerulosclerosis Market Dynamics

Drivers

• Increased Prevalence of Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is a rare health condition affecting about 210,200 patients globally and around 14,000 to 16,000 new cases are diagnosed annually. The increasing numbers along the considerable opportunities are boosting the growth of the market.

• Higher Therapeutic Options

The latest therapy for the primary FSGS includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Additionally, steroid therapy is among the most basic and standard treatment with oral prednisone. Some of the main evolving companies having their potential drug candidates in the pipeline are Chemocentryx, Pharmaceuticals, Retrophin Inc., Reata, and Vertex Pharmaceuticals. This boosts the market growth.

Opportunities

• Growing Elderly Population

Life expectancy is increasing all over the globe, which has led to an upsurge in the elderly population. This trend positively impacts the industry by increasing the disease occurrence and creating per capita demand for its remedies. A rise in elderly visits to outpatient facilities and ambulatory surgery centers (ASC) results in the sound growth of the focal segmental glomerulosclerosis market during the forecast period. Thus, it creates more opportunities for the market growth.

• Increased Diagnostic Tests

Several advances in pathogenesis of focal segmental glomerular sclerosis (FSGS) resulted in the market for research in the focal segmental glomerular sclerosis (FSGS). Several etiologies drive focal segmental glomerulosclerosis (FSGS). Rising awareness about occurrence of kidney disease drive prospects in the FSGS market. Given the increased mortality in patient populations, important advances were made in genetic testing, lab testing, and kidney biopsies. These new treatment methods are creating more opportunities for the market.

 Restraints/Challenges

• Lack of Medical Care

The lack of medical care in undeveloped economies may restrain the growth of focal segmental glomerulosclerosis market during the forecast period. Not much awareness leads to the unavailability of treatment and limits market growth.

• High Cost

The huge expenditure associated with drug therapy, dialysis, kidney transplant hamper the market growth. The huge drug development and associated processes hamper the market's growth.

Global Focal Segmental Glomerulosclerosis Market Scope

The focal segmental glomerulosclerosis market is segmented on the basis of type, treatment, route of administration, end-user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Primary
• Secondary

Treatment

• Drug Therapy
• Dialysis
• Kidney Transplant
• Others

Route of Administration

• Oral
• Parenteral

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Focal Segmental Glomerulosclerosis Market Regional Analysis/Insights

The focal segmental glomerulosclerosis market is analyzed and market size insights and trends are provided by country type, treatment, route of administration, end-user, and distribution channel as referenced above.

The countries covered in the market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Kuwait, Egypt, and rest of Middle East & Africa.

North America is expected to dominate the market due to the high diagnostic rate and presence of key players in this region.

Asia-Pacific is expected to show significant growth in the market throughout the forecasted period due to the growing cases of kidney disorder, the presence of sophisticated medical facilities to maximize the treatment effectiveness for a patient suffering from glomerular disease, and increased focus on research and development activity.

The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Le marché de la glomérulosclérose segmentaire focale vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les équipements en capital, la base installée de différents types de produits pour le marché de la glomérulosclérose segmentaire focale, l'impact de la technologie utilisant les courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché de la glomérulosclérose segmentaire focale. Les données sont disponibles pour la période historique 2010-2020.

Analyse du paysage concurrentiel et des parts de marché mondiales de la glomérulosclérose segmentaire focale

Le paysage concurrentiel du marché de la glomérulosclérose segmentaire focale fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de la glomérulosclérose segmentaire focale.

Certains des principaux acteurs opérant sur le marché de la glomérulosclérose segmentaire focale sont :

• Pfizer Inc (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Fresenius Kabi AG (Allemagne)
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Novartis SA (Suisse)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Société Bristol Myers Squibb (États-Unis)
• GSK Plc. (Royaume-Uni)
• Bayer AG (Allemagne)
• Sun Pharmaceutical Industries Ltd (Inde)
• Accord Healthcare (Royaume-Uni)
• Wockhardt (Inde)

SKU-54440